Reducing Tobacco Harm: Finding the Best Route for Africa

Aug.15.2022
Reducing Tobacco Harm: Finding the Best Route for Africa
Reducing tobacco harm is a public health strategy that advocates for harm reduction products as a practical approach to lower smoking rates.

The entire world agrees that smoking rates need to be decreased. Whether it's the ubiquitous cigarette or local cigars and hookahs known as shisha in Nigeria, all stakeholders want to reduce smoking rates, and in fact, keep reducing them. While cigarettes have always received the most attention, people are now beginning to recognize the dangers of shisha, especially as it becomes increasingly popular among young people.


However, the means to achieve the expected decrease in smoking rates continue to cause debate among various parties. The popular African saying, "there are different paths to reach the same destination" is a subtle way our ancestors chose to remind us that the destination is the ultimate goal. Naturally, as long as the expected destination or established objective is reached, everything is fair and great, without any mistakes made along the way.


In fact, this motto has never been more important than in the process of reducing smoking rates in Africa today. While the debate about the path to this destination continues, prohibitionists – those who believe that only complete abstinence from smoking can achieve a decrease in smoking rates – continue to denigrate advocates for harm reduction, while also denying the success of harm reduction plans.


The photo, taken by Haim Charbit on Unsplash, represents a public health strategy called tobacco harm reduction (THR), which aims to reduce personal and wider societal health risks associated with combustible tobacco products. This approach is based on the understanding that most of the harm related to combustible tobacco is caused by the chemical mixture released when tobacco is burned (smoked) and then inhaled. However, if you remove the smoking/burning element, the risk of consuming tobacco is significantly reduced.


THR advocates believe that many adult smokers who wish to quit smoking often struggle or cannot quit, while others wish to continue to enjoy nicotine without harmful effects. Therefore, these smokers should switch to alternative products that release nicotine without burning tobacco. The word "switching" is an effective term for THR advocates, who prioritize the freedom to switch and the availability of alternative options. Providing information on alternative or reduced-risk products is a key driver of effective THR strategies for adult consumers to make informed choices.


Recently, advocates of tobacco harm reduction (THR) have been promoting their cause in Africa by explaining the science behind the concept and citing successful records from countries that have accepted the ideology of reducing tobacco harm. It is worth noting that THR advocates still agree that quitting smoking is the best choice and frequently emphasize this fact. However, they have chosen a pragmatic approach because they understand that both quitting smoking and switching will achieve the goal of reducing smoking rates. The position of THR advocates is supported by scientific evidence from more developed economies, which recognizes that adopting and effectively implementing tobacco harm reduction strategies can significantly reduce smoking rates. For example, the United Kingdom has recognized the effectiveness of reducing tobacco harm or substituting tobacco products in lowering smoking rates. The National Institute for Health and Care Excellence (NICE), which publishes evidence-based guidelines for the most effective methods of disease prevention, diagnosis, and treatment, has also released guidelines for tobacco harm reduction. The guidelines acknowledge that quitting smoking is always the best choice for smokers, but they support the use of licensed nicotine-containing products (NCPs) to help smokers who are currently unable to quit transition to less harmful options.


The Food and Drug Administration (FDA) of the United States of America (USA) has begun to classify alternative products as "reduced-risk tobacco products". This is a clear indication that the country is relying on scientific and verified evidence to provide guidance on reducing tobacco harm.


According to reports, Japan's smoking rate has decreased by 34% primarily due to the introduction of alternative products that give citizens the opportunity to switch to lower-risk options rather than outright quitting. This was detailed in a report by renowned consultancy firm Frost & Sullivan in December 2020, which also emphasized the importance of establishing effective regulation.


In Canada, the government has released a scientifically-supported statement through the Canadian Ministry of Health, stating that "completely replacing smoking with e-cigarettes will reduce your exposure to harmful chemicals" and "e-cigarette products and e-cigarettes release nicotine in a smaller way than smoking." Others are advising adult smokers to stay away from combustible tobacco products. The Canadian Public Health Association also recognizes the efficacy of alternative products and has released statements since 2018 acknowledging that the risks associated with alternative nicotine delivery products are lower than combustible tobacco.


New Zealand's Ministry of Health launched a website called Vaping Facts in 2019 with the aim of educating citizens about the realities of using e-cigarettes as a smoking cessation tool. The website encourages smokers to consider e-cigarettes as a means of quitting smoking and widely disseminates content indicating that the risks associated with vaping are lower than with smoking. This is another clear example of a country using a scientific and fact-based approach to reduce the harm caused by tobacco.


African countries need to conduct independent evaluations of each potential pathway towards reducing smoking rates. Their health departments and other health organizations, including academic members, must commission independent research focused not only on reducing tobacco harm but also examining the numerous public health issues affecting their citizens. This will aid in determining the best policies and regulatory frameworks to effectively promote smoking cessation and reduce tobacco harm simultaneously.


Statement


This article is compiled from third-party information and is intended for industry professionals for communication and learning purposes.


This article does not represent the views of 2FIRSTS, and 2FIRSTS cannot confirm the authenticity or accuracy of the content. The translation of this article is only for industry exchange and research purposes.


Due to limitations in the skill level of the translator, the translation may not accurately reflect the original text. Please refer to the original text for accuracy.


2FIRSTS maintains complete alignment with the Chinese government's positions and statements regarding domestic issues, as well as those concerning Hong Kong, Macau, Taiwan, and international relationships.


The copyright of compiled information belongs to the original media and author. If there is any infringement, please contact us for deletion.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Bret Koplow Takes Permanent Charge of FDA Tobacco Center After Pushing Faster PMTA Reviews, as HHS Emphasizes Innovation and Access to Lower-Risk Alternatives
Bret Koplow Takes Permanent Charge of FDA Tobacco Center After Pushing Faster PMTA Reviews, as HHS Emphasizes Innovation and Access to Lower-Risk Alternatives
The U.S. Department of Health and Human Services has named Bret Koplow permanent director of the FDA’s Center for Tobacco Products, ending his period as acting chief. Koplow has spent years working on tobacco regulation, law and policy inside the FDA and, while serving as acting director, pushed for faster PMTA reviews and nicotine pouch review pilots. HHS also said CTP will prioritize innovation and access to less harmful alternatives for adult smokers while continuing efforts to protect youth.
Sep.09
Product | BAT Expands VELO Travellers’ Collection With Mexico, Spain and Sweden Summer Edition Nicotine Pouches
Product | BAT Expands VELO Travellers’ Collection With Mexico, Spain and Sweden Summer Edition Nicotine Pouches
British American Tobacco (BAT) Global Travel Retail has expanded the VELO Travellers’ Collection with three new Summer Editions: Mexico, Spain and Sweden. Inspired by destination themes, the new nicotine pouch variants are designed for global travel-retail channels. The launch further strengthens VELO’s positioning as a travel-retail exclusive product collection.
Aug.27
PMI Expands U.S. ZYN Portfolio With New 1.5 mg and 8 mg Strengths, Moves Toward a Unified 20-Pouch-Per-Can Format
PMI Expands U.S. ZYN Portfolio With New 1.5 mg and 8 mg Strengths, Moves Toward a Unified 20-Pouch-Per-Can Format
Philip Morris International is expanding its U.S. ZYN nicotine pouch portfolio with new 1.5 mg and 8 mg strengths and plans to move its core 3 mg and 6 mg dry-pouch products from 15 to 20 pouches per can in the fourth quarter of 2026. ZYN ULTRA is also commercially available, with FDA authorization covering 10 products at 9 mg and one 11 mg Smooth product. PMI U.S. lists the new 1.5 mg and 8 mg strengths as commercially available, but as of September 10 they do not appear on the FDA’s public authorization list. Public materials do not identify which PMTA submissions cover the two new strengths or their current review status.
Sep.11
RLX Technology Dropped From FTSE All-World as International Business Reaches 68.5% of Q2 Revenue
RLX Technology Dropped From FTSE All-World as International Business Reaches 68.5% of Q2 Revenue
RLX Technology (NYSE: RLX) has been removed from the FTSE All-World Index, effective September 21. FTSE Russell records show RLX was already part of its global equity index universe by 2022, when its American depositary receipts were classified as China Large Cap securities. Trading volume rose to about 44.77 million shares on September 18, roughly 23 times the previous session's volume. RLX reported RMB1.0105 billion in second-quarter revenue, up 14.8% year over year, with international operations contributing 68.5%. The company also acquired a 51% stake in one of Western Europe's largest distributors of next-generation smoke-free and FMCG products in July.
Sep.22
PMI's IQOS Extends ZAMNA Electronic-Music Partnership to Spain as Vogue España Publishes Branded Content
PMI's IQOS Extends ZAMNA Electronic-Music Partnership to Spain as Vogue España Publishes Branded Content
Philip Morris International's IQOS has extended its partnership with electronic-music event brand ZAMNA to Spain, setting up a House of IQOS at ZAMNA Madrid. Vogue España and Time Out Madrid subsequently published branded content clearly labeled as collaborations with IQOS. PMI has also expanded its company-owned IQOS boutique network in Spain to seven cities this year. The company says IQOS's adjusted heated-tobacco market share in Europe reached 12.6% in the first quarter of 2026, with Spain among its stronger-performing European markets.
Sep.20
South Korea Extends Vape Rules to Unmanned Stores After Bringing Synthetic Nicotine Under Tobacco Law
South Korea Extends Vape Rules to Unmanned Stores After Bringing Synthetic Nicotine Under Tobacco Law
South Korea's Ministry of Gender Equality and Family said on September 14 that it plans to designate unmanned e-cigarette stores as businesses where minors are prohibited from entering or working. Operators would be required to verify customers' ages and display notices restricting access by minors. The proposal is open for public comment through October 6. The move follows an April expansion of South Korea's statutory tobacco definition that brought products made with natural or synthetic nicotine under the Tobacco Business Act. Nicotine-free liquids and products using nicotine analogues such as 6-methylnicotine, however, remain an emerging regulatory issue.
Sep.21